Moon Jeonghui, Jung Younghun, Moon Seokoh, Hwang Jaehyeon, Kim Soomin, Kim Mi Soo, Yoon Jeong Hyeon, Kim Kyeongwon, Park Youngseo, Cho Jae Youl, Kweon Dae-Hyuk
Department of Integrative Biotechnology, College of Biotechnology and Bioengineering, Sungkyunkwan University, Suwon, Republic of Korea.
J Ginseng Res. 2023 Jan;47(1):123-132. doi: 10.1016/j.jgr.2022.07.003. Epub 2022 Jul 15.
Pseudotyped virus systems that incorporate viral proteins have been widely employed for the rapid determination of the effectiveness and neutralizing activity of drug and vaccine candidates in biosafety level 2 facilities. We report an efficient method for producing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pseudovirus with dual luciferase and fluorescent protein reporters. Moreover, using the established method, we also aimed to investigate whether Korean Red Ginseng (KRG), a valuable Korean herbal medicine, can attenuate infectivity of the pseudotyped virus.
A pseudovirus of SARS-CoV-2 (SARS-2pv) was constructed and efficiently produced using lentivirus vector systems available in the public domain by the introduction of critical mutations in the cytoplasmic tail of the spike protein. KRG extract was dose-dependently treated to Calu-3 cells during SARS2-pv treatment to evaluate the protective activity against SARS-CoV-2.
The use of Calu-3 cells or the expression of angiotensin-converting enzyme 2 (ACE2) in HEK293T cells enabled SARS-2pv infection of host cells. Coexpression of transmembrane protease serine subtype 2 (TMPRSS2), which is the activator of spike protein, with ACE2 dramatically elevated luciferase activity, confirming the importance of the TMPRSS2-mediated pathway during SARS-CoV-2 entry. Our pseudovirus assay also revealed that KRG elicited resistance to SARS-CoV-2 infection in lung cells, suggesting its beneficial health effect.
The method demonstrated the production of SARS-2pv for the analysis of vaccine or drug candidates. When KRG was assessed by the method, it protected host cells from coronavirus infection. Further studies will be followed for demonstrating this potential benefit.
包含病毒蛋白的假型病毒系统已被广泛用于在生物安全2级设施中快速测定候选药物和疫苗的有效性及中和活性。我们报告了一种利用双荧光素酶和荧光蛋白报告基因生产严重急性呼吸综合征冠状病毒2(SARS-CoV-2)假病毒的有效方法。此外,我们还旨在利用已建立的方法研究珍贵的韩国草药高丽参(KRG)是否能减弱假型病毒的感染性。
通过在刺突蛋白的胞质尾引入关键突变,利用公共领域可用的慢病毒载体系统构建并高效生产了SARS-CoV-2假病毒(SARS-2pv)。在SARS2-pv处理期间,将KRG提取物以剂量依赖的方式处理Calu-3细胞,以评估其对SARS-CoV-2的保护活性。
使用Calu-3细胞或在HEK293T细胞中表达血管紧张素转换酶2(ACE2)可使宿主细胞感染SARS-2pv。作为刺突蛋白激活剂的跨膜蛋白酶丝氨酸2型(TMPRSS2)与ACE2共表达可显著提高荧光素酶活性,证实了TMPRSS2介导的途径在SARS-CoV-2进入过程中的重要性。我们的假病毒检测还显示,KRG可诱导肺细胞对SARS-CoV-2感染产生抗性,表明其对健康有益。
该方法证明了可生产用于分析候选疫苗或药物的SARS-2pv。当用该方法评估KRG时,它可保护宿主细胞免受冠状病毒感染。后续将进行进一步研究以证明这种潜在益处。